Adverse events related to drug-drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era : a systematic review
INTRODUCTION: Since COVID-19 patients are often polytreated, monitoring drug-drug interaction (DDIs) is necessary. We evaluated whether drugs used after the second COVID-19 pandemic wave were associated with DDI-related adverse events and the role of drug interaction checkers in identifying them.
METHODS: The study (PROSPERO-ID: CRD42024507634) included: 1) consulting the drug interaction checkers Drugs.com, Liverpool COVID-19 Interactions, LexiComp, Medscape, and Micromedex; 2) systematic review; 3) reviewed studies analysis; 4) evaluating drug interaction checkers potential to anticipate DDI-related adverse events.The systematic review was performed searching PubMed, Scopus, ScienceDirect, and Cochrane databases from 1 March 2022 to 11 November 2023. Observational studies, and clinical trials were included. Article without reporting direct association between DDIs and adverse events were excluded. The risk of bias was assessed by Newcastle-Ottawa scale.
RESULTS: The most frequent DDIs involved nirmatrelvir/ritonavir (N/R) and fluvoxamine. Fifteen studies, including 150 patients and 35 DDI-related outcomes, were analyzed. The most frequent DDIs involved tacrolimus with N/R, resulting in creatinine increase.Eighty percent of reported DDI-related adverse events would have been identified by all drug-interaction checkers, while the remaining 20% by at least 2 of them.
CONCLUSIONS: Drug interaction checkers are useful but show inconsistencies. Multiple sources are needed to tailor treatment in the context of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Expert opinion on drug metabolism & toxicology - 20(2024), 4 vom: 01. Apr., Seite 275-292 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Conti, Valeria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse outcomes |
|---|
| Anmerkungen: |
Date Completed 25.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17425255.2024.2339397 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370575113 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370575113 | ||
| 003 | DE-627 | ||
| 005 | 20240425233439.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240404s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17425255.2024.2339397 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370575113 | ||
| 035 | |a (NLM)38568077 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Conti, Valeria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adverse events related to drug-drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era |b a systematic review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Since COVID-19 patients are often polytreated, monitoring drug-drug interaction (DDIs) is necessary. We evaluated whether drugs used after the second COVID-19 pandemic wave were associated with DDI-related adverse events and the role of drug interaction checkers in identifying them | ||
| 520 | |a METHODS: The study (PROSPERO-ID: CRD42024507634) included: 1) consulting the drug interaction checkers Drugs.com, Liverpool COVID-19 Interactions, LexiComp, Medscape, and Micromedex; 2) systematic review; 3) reviewed studies analysis; 4) evaluating drug interaction checkers potential to anticipate DDI-related adverse events.The systematic review was performed searching PubMed, Scopus, ScienceDirect, and Cochrane databases from 1 March 2022 to 11 November 2023. Observational studies, and clinical trials were included. Article without reporting direct association between DDIs and adverse events were excluded. The risk of bias was assessed by Newcastle-Ottawa scale | ||
| 520 | |a RESULTS: The most frequent DDIs involved nirmatrelvir/ritonavir (N/R) and fluvoxamine. Fifteen studies, including 150 patients and 35 DDI-related outcomes, were analyzed. The most frequent DDIs involved tacrolimus with N/R, resulting in creatinine increase.Eighty percent of reported DDI-related adverse events would have been identified by all drug-interaction checkers, while the remaining 20% by at least 2 of them | ||
| 520 | |a CONCLUSIONS: Drug interaction checkers are useful but show inconsistencies. Multiple sources are needed to tailor treatment in the context of COVID-19 | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adverse outcomes | |
| 650 | 4 | |a SARS-CoV2 pandemic | |
| 650 | 4 | |a drug interaction checker | |
| 650 | 4 | |a nirmaltrevir-ritonavir | |
| 650 | 4 | |a tacrolimus | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Bertini, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Ricciardi, Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Stefanelli, Berenice |e verfasserin |4 aut | |
| 700 | 1 | |a De Bellis, Emanuela |e verfasserin |4 aut | |
| 700 | 1 | |a Sellitto, Carmine |e verfasserin |4 aut | |
| 700 | 1 | |a Cascella, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Sabbatino, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Corbi, Graziamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Pagliano, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Filippelli, Amelia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug metabolism & toxicology |d 2005 |g 20(2024), 4 vom: 01. Apr., Seite 275-292 |w (DE-627)NLM164308237 |x 1744-7607 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:4 |g day:01 |g month:04 |g pages:275-292 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17425255.2024.2339397 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 4 |b 01 |c 04 |h 275-292 | ||